^
    8ms
    Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=13, Completed, Kyowa Kirin Co., Ltd. | N=72 --> 13
    Enrollment change • Metastases
    |
    KW-2450
    8ms
    Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=11, Terminated, Kyowa Kirin Co., Ltd. | Phase classification: P1/2 --> P1
    Phase classification • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 overexpression
    |
    lapatinib • letrozole • KW-2450